Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SmofKabiven Extra Nitrogen vs Olimel N9E in Critical Illness
NCT03992716Phase 4Terminated
- Sponsor
- Fresenius Kabi
- Start
- Nov 2019
- Primary completion
- Mar 2020
- Modality
- Nanoparticles
- Countries
- 3
01
Overview
Phase 4, randomised, single-blind trial of SmofKabiven Peripheral in critical illness (2 arms), sponsored by Fresenius Kabi. Primary endpoint: Proportion of patients reaching ≥70% of the cumulative target for protein delivery. Started Nov 2019; status: terminated.
02
Drugs
SmofKabiven Peripheral
03
Conditions
critical illness
Beyond the preview
Go deeper on NCT03992716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03992716.